Literature DB >> 16395140

Occult with no classic choroidal neovascularization secondary to age-related macular degeneration treated by intravitreal triamcinolone and photodynamic therapy with verteporfin.

Massimo Nicolò1, Davidina Ghiglione, Silvio Lai, Francesca Nasciuti, Simonetta Cicinelli, Giovanni Calabria.   

Abstract

PURPOSE: To examine combined treatment with intravitreal triamcinolone acetonide (IVT) and photodynamic therapy (PDT) for occult with no classic choroidal neovascularization (CNV) secondary to age-related macular degeneration.
METHODS: In this prospective, interventional case series, 11 eyes of 10 consecutive patients with occult with no classic CNV underwent a single injection (25 mg) of IVT followed 1 month later by PDT. Best-corrected visual acuity was measured by Early Treatment Diabetic Retinopathy Study (ETDRS) protocol refraction.
RESULTS: Median best-corrected visual acuity was 20/160, 20/80, 20/80, 20/50, and 20/80 at baseline and 1, 3, 6, and 12 months, respectively. Best-corrected visual acuity at baseline was statistically different (P < 0.05) than best-corrected visual acuity at 1, 3, and 6 months. Of 11 eyes, 5 (45.5%), 7 (63.6%), 7 (63.6%), and 4 (36.3%) had improved best-corrected visual acuity of at least 3 ETDRS lines at 1, 3, 6, and 12 months, respectively, while 6 (54.5%), 9 (81.8%), 10 (91%), and 8 (73%) had improved best-corrected visual acuity of at least 2 ETDRS lines at 1, 3, 6, and 12 months, respectively. Two eyes (18%) lost >3 lines at 12 months. One eye had intraocular hypertension at 3 months and was treated with a combination of topical antiglaucomatous drugs. One eye developed a dense cataract at the last follow-up visit. No endophthalmitis, retinal detachment, or vitreous hemorrhage developed. Fluorescein leakage and retinal thickness reduced significantly after treatment.
CONCLUSIONS: Improvement of best-corrected visual acuity and lack of fluorescein leakage suggest combination treatment with IVT and PDT for occult with no classic CNV merits further investigation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16395140     DOI: 10.1097/00006982-200601000-00010

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  10 in total

1.  Focal macular electroretinograms after photodynamic therapy combined with intravitreal bevacizumab.

Authors:  Kohei Ishikawa; Hiroaki Nishihara; Shinsuke Ozawa; Chang-Hua Piao; Yasuki Ito; Mineo Kondo; Hiroko Terasaki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-10-31       Impact factor: 3.117

2.  Treatment of recurrent retinal angiomatous proliferation with intravitreal triamcinolone acetonide followed by photodynamic therapy with verteporfin: A retrospective case series.

Authors:  Nicola Cardascia; Claudio Furino; Andrea Ferrara; Francesco Boscia; Giovanni Alessio
Journal:  Curr Ther Res Clin Exp       Date:  2009-06

3.  Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study.

Authors:  Wai-Man Chan; Timothy Y Y Lai; Amy L Wong; David T L Liu; Dennis S C Lam
Journal:  Br J Ophthalmol       Date:  2006-09-20       Impact factor: 4.638

4.  Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).

Authors:  Rogério A Costa; Rodrigo Jorge; Daniela Calucci; Luiz A S Melo; José A Cardillo; Ingrid U Scott
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-02-28       Impact factor: 3.117

5.  Combination therapy for choroidal neovascularisation.

Authors:  Albert J Augustin; Indre Offermann
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

6.  Combined photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: effect of initial visual acuity on treatment response.

Authors:  Ramin Schadlu; Steven M Kymes; Rajendra S Apte
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-06-22       Impact factor: 3.117

7.  Retinal angiomatous proliferation treated by intravitreal triamcinolone and photodynamic therapy with verteporfin.

Authors:  Massimo Nicolò; Davidina Ghiglione; Silvio Lai; Giovanni Calabria
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-08       Impact factor: 3.117

8.  Oscillatory photodynamic therapy for choroidal neovascularization and central serous retinopathy; a pilot study.

Authors:  Gholam A Peyman; Michael Tsipursky; Nariman Nassiri; Mandi Conway
Journal:  J Ophthalmic Vis Res       Date:  2011-07

9.  Combined treatment of exudative age related macular degeneration with photodynamic therapy and intravitreal triamcinolone.

Authors:  José M Ruiz-Moreno; Javier A Montero
Journal:  Clin Ophthalmol       Date:  2008-03

Review 10.  Use of intravitreal injection of triamcinolone acetonide in the treatment of age-related macular degeneration.

Authors:  Lekha Gopal; Tarun Sharma
Journal:  Indian J Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 1.848

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.